The estimated Net Worth of Richard A Md Miller is at least $3.74 Milion dollars as of 6 May 2024. Mr. Miller owns over 577,634 units of Corvus Pharmaceuticals Inc stock worth over $2,639,787 and over the last 9 years he sold CRVS stock worth over $0. In addition, he makes $1,098,040 as Chairman of the Board, President a Chief Executive Officer at Corvus Pharmaceuticals Inc.
Richard has made over 23 trades of the Corvus Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 577,634 units of CRVS stock worth $999,307 on 6 May 2024.
The largest trade he's ever made was buying 577,634 units of Corvus Pharmaceuticals Inc stock on 6 May 2024 worth over $999,307. On average, Richard trades about 31,688 units every 81 days since 2016. As of 6 May 2024 he still owns at least 577,634 units of Corvus Pharmaceuticals Inc stock.
You can see the complete history of Mr. Miller stock trades at the bottom of the page.
Richard A. Miller M.D. serves as Chairman of the Board, President, Chief Executive Officer of the Company. Dr. Miller was Chairman and Chief Executive Officer of Graphea, Inc., a privately-held chemical company, which he founded. Dr. Miller served as Chief Commercialization Officer, Associate Dean and Research Professor in Chemistry at The University of Texas at Austin from September 2010 to December 2011. Dr. Miller founded Principia Biopharma Inc., a privately-held biopharmaceutical company, and served as its President and Chief Executive Officer and a member of its board of directors from January 2009 to February 2011. He served as President, Chief Executive Officer and Director of Pharmacyclics, Inc., a public biopharmaceutical company, from 1991, when he co-founded the company, to 2008. At Pharmacyclics, Dr. Miller led the initial discovery and development efforts for ibrutinib. Dr. Miller was a co-founder, Vice President and Director of IDEC Pharmaceuticals Corporation, a biotechnology company that merged with Biogen, Inc. in June 2003, where he led research efforts on lymphoma leading to the development of rituximab. Dr. Miller has been Adjunct Clinical Professor of Medicine (Oncology) at Stanford University Medical Center since 1991. Dr. Miller received a B.A. in Chemistry from Franklin & Marshall College and an M.D. from the State University of New York Medical School. He is board certified in both Internal Medicine and Medical Oncology.
As the Chairman of the Board, President a Chief Executive Officer of Corvus Pharmaceuticals Inc, the total compensation of Richard Miller at Corvus Pharmaceuticals Inc is $1,098,040. There are 2 executives at Corvus Pharmaceuticals Inc getting paid more, with Daniel Hunt having the highest compensation of $1,554,080.
Richard Miller is 69, he's been the Chairman of the Board, President a Chief Executive Officer of Corvus Pharmaceuticals Inc since 2014. There are 1 older and 16 younger executives at Corvus Pharmaceuticals Inc. The oldest executive at Corvus Pharmaceuticals Inc is Dr. Richard A. Miller M.D., 70, who is the Co-Founder, Pres, CEO & Chairman.
Richard's mailing address filed with the SEC is C/O CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME, CA, 94010.
Over the last 9 years, insiders at Corvus Pharmaceuticals Inc have traded over $52,808,904 worth of Corvus Pharmaceuticals Inc stock and bought 11,523,300 units worth $85,214,510 . The most active insiders traders include Holdings A/S Novo, Street Partners Llc Adams a Capital, Llc Eco R1. On average, Corvus Pharmaceuticals Inc executives and independent directors trade stock every 46 days with the average trade being worth of $1,530,854. The most recent stock trade was executed by William Benton Jones on 6 May 2024, trading 20,000 units of CRVS stock currently worth $34,600.
corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.
Corvus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: